TPI 287 in Breast Cancer Metastatic to the Brain

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 16, 2011

Primary Completion Date

April 14, 2017

Study Completion Date

April 14, 2017

Conditions
Breast Cancer
Interventions
DRUG

TPI 287

"Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.~Starting Dose Phase II: Maximum tolerated dose from Phase I."

DRUG

Dexamethasone

6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.

DRUG

Benadryl

12.5-25 mg intravenous (IV) push 30-60 minutes prior

DRUG

Ranitidine

As H2 blocker 1mg/kg IV 30-60 minutes prior

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Cortice Biosciences, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01332630 - TPI 287 in Breast Cancer Metastatic to the Brain | Biotech Hunter | Biotech Hunter